Cosmo Pharmaceuticals Strengthens Partnership with RedHill Biopharma with Manufacturing Agreement for Movantik, RHB-204 and Opaganib
Cosmo Pharmaceuticals NV today announced an agreement with RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill”) to manufacture three key products; Movantik® (RedHill’s largest selling product in the U.S.), RHB-204 (currently in a Phase III U.S. study as a stand-alone first-line treatment for pulmonary nontuberculous mycobacteria (NTM) disease) and opaganib (a new, orally-administered, chemical entity currently in a global Phase II/III study for treatment of COVID-19 pneumonia). These agreements provide secure high-quality manufacturing capacity for all three products.